William Haskel, Paratek's Chief Legal Officer, General Counsel, and Corporate Secretary, has been with the company since June 2015.
From 2011 until March 2015, Mr. Haskel served as the Senior Vice President, General Counsel, Chief Compliance Officer and Corporate Secretary at Cambrex Corporation, where he reported to the CEO, and was a member of core management committees. Mr. Haskel provided counsel to the Board of Directors, CEO, and senior management, and was responsible for the global law function as well as overseeing Global Regulatory and Quality Affairs, and Environment, Health and Safety. He was a principal adviser for Board and Governance, M&A, Securities and Corporate matters.
Previously, Mr. Haskel enjoyed an 18-year career of progressive responsibilities at Wyeth, which was acquired by Pfizer in 2009 in a transaction valued at $68 billion. There, he served as Vice President and Associate General Counsel-Corporate where he was a key advisor to executive management and managed a group of 33 employees/19 lawyers across corporate and pharmaceutical division headquarters, and led legal teams on a series of complex multi-billion dollar global transactions that drove the Company's transition from a diversified holding company to a focused health care company. Mr. Haskel also served as Vice President, Global Administration where he led a newly formed global department charged with designing and executing global strategies to capture cost savings and business efficiencies in light of the new health care environment. During this time, Mr. Haskel also served as Advisor for the Pfizer Transaction and was a leader of the successful integration of Wyeth into Pfizer.
Earlier at Wyeth, Mr. Haskel was selected to be the Assistant Vice President, Planning; Assistant to the Chairman, President and CEO; and Secretary of Wyeth Management Committee. Earlier in his career, Mr. Haskel was a corporate associate at the law firms Hale & Dorr (now WilmerHale) in Boston, and Olwine, Connelly, Chase, O'Donnell & Weyher in New York City.
Education & Accomplishments
Mr. Haskel received his J.D. from George Washington University Law School; his B.A. from Franklin and Marshall College; and has Bar Admissions in New York State; Commonwealth of Massachusetts; New Jersey (Limited In-House License), and the United States District Court (District of Massachusetts).
What is William M. Haskel's net worth?
The estimated net worth of William M. Haskel is at least $996,863.52 as of August 9th, 2023. Mr. Haskel owns 447,024 shares of Paratek Pharmaceuticals stock worth more than $996,864 as of April 17th. This net worth estimate does not reflect any other investments that Mr. Haskel may own. Learn More about William M. Haskel's net worth.
How old is William M. Haskel?
Mr. Haskel is currently 61 years old. There are 5 older executives and no younger executives at Paratek Pharmaceuticals. The oldest executive at Paratek Pharmaceuticals is Mr. Michael F. Bigham CPA, CPA, M.B.A., MBA, Exec. Chairman, who is 65 years old. Learn More on William M. Haskel's age.
How do I contact William M. Haskel?
Has William M. Haskel been buying or selling shares of Paratek Pharmaceuticals?
William M. Haskel has not been actively trading shares of Paratek Pharmaceuticals during the past quarter. Most recently, William M. Haskel sold 34,526 shares of the business's stock in a transaction on Wednesday, August 9th. The shares were sold at an average price of $2.20, for a transaction totalling $75,957.20. Following the completion of the sale, the general counsel now directly owns 447,024 shares of the company's stock, valued at $983,452.80. Learn More on William M. Haskel's trading history.
Who are Paratek Pharmaceuticals' active insiders?
Are insiders buying or selling shares of Paratek Pharmaceuticals?
During the last year, insiders at the specialty pharmaceutical company sold shares 4 times. They sold a total of 142,346 shares worth more than $313,161.20. The most recent insider tranaction occured on August, 9th when insider Randall B Brenner sold 27,603 shares worth more than $60,726.60. Insiders at Paratek Pharmaceuticals own 8.0% of the company.
Learn More about insider trades at Paratek Pharmaceuticals. Information on this page was last updated on 8/9/2023.
